PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research

Principle and Setup: The Science Behind PF-562271 HCl

PF-562271 HCl is a potent, reversible ATP-competitive inhibitor that targets both focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), playing a pivotal role in cancer research. As a non-receptor tyrosine kinase, FAK orchestrates cell adhesion, migration, survival, and tumor microenvironment modulation, often becoming dysregulated in cancer progression and metastasis. PF-562271 HCl distinguishes itself with an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, providing approximately 10-fold selectivity for FAK and over 100-fold selectivity versus most other kinases, except some cyclin-dependent kinases (CDKs). This selectivity profile is critical for researchers aiming to precisely dissect the focal adhesion kinase signaling pathway without off-target effects.

Supplied by APExBIO, PF-562271 HCl is formulated as a hydrochloride salt, ensuring enhanced stability and handling. It is highly soluble in DMSO (≥26.35 mg/mL with gentle warming), but insoluble in water and ethanol, necessitating specific solvent preparation for cell-based and in vivo assays. Proper storage at -20°C and prompt use of solutions maximize compound integrity and reproducibility.

Step-by-Step Experimental Workflow Enhancements

1. Compound Preparation

• Weigh out PF-562271 HCl powder in a desiccated environment to minimize moisture uptake.
• Dissolve in DMSO to a stock concentration of 10–20 mM, applying gentle warming if needed.
• Aliquot and store stocks at -20°C; avoid repeated freeze-thaw cycles.
• Prepare fresh working solutions on the day of use, diluting to desired concentrations in cell culture medium or suitable buffers, maintaining final DMSO below 0.1% (v/v) to limit cytotoxicity.

2. Cell-Based Assays

• Cell Viability/Proliferation: Seed cancer cell lines (e.g., breast, ovarian, or endometrial) at optimal density. Treat with serial dilutions of PF-562271 HCl (typically 0.1 nM to 10 μM) and incubate 24–96 hours. Assess viability via MTT, CellTiter-Glo, or similar assays.
• Migration/Invasion: Employ transwell or wound-healing assays. Pre-treat cells with PF-562271 HCl for 1–4 hours; monitor migration/invasion rates compared to controls.
• Phosphorylation Inhibition: After compound exposure (e.g. 1–2 hours), harvest cells and perform Western blotting for p-FAK (Y397), p-Pyk2, and downstream effectors (e.g., p-Akt, p-ERK).

3. In Vivo Tumor Models

• Prepare PF-562271 HCl in a suitable vehicle (DMSO, PEG400, or saline with surfactant) for oral or intraperitoneal dosing.
• Administer to tumor-bearing mice at previously validated doses (e.g., 25–50 mg/kg), monitoring tumor volume and metastasis over time.
• Collect tissues for analysis of FAK phosphorylation inhibition and downstream signaling.

A comprehensive protocol guide elaborates on these workflows, providing additional tips for optimizing FAK/Pyk2 inhibitor studies and maximizing reproducibility in translational oncology.

Advanced Applications and Comparative Advantages

PF-562271 HCl’s nanomolar potency and specificity afford unique advantages in both foundational and translational cancer research:

• Dissecting FAK/Pyk2 Signaling: The ability of PF-562271 HCl to inhibit FAK phosphorylation with an EC₅₀ of 93 ng/mL in tumor-bearing mice enables detailed mechanistic studies, including modulation of cell adhesion, migration, and survival pathways relevant to tumor growth and metastasis.
• Tumor Microenvironment Modulation: By disrupting FAK/Pyk2 signaling, researchers can probe interactions between cancer cells, stromal cells, and the extracellular matrix, providing insight into invasion and metastatic processes.
• Resistance Mechanisms: Studies like Keller et al. (2023) underscore the importance of targeting kinases and metabolic pathways in therapy-resistant cancers. PF-562271 HCl offers a powerful tool to evaluate compensatory FAK/Pyk2 upregulation in HER2-targeted therapy-resistant breast cancer, complementing approaches that target EDI3 and choline metabolism.
• Pharmacological Benchmarking: Compared to less selective FAK inhibitors, PF-562271 HCl's high selectivity enhances confidence in target engagement and reduces confounding off-target effects, as highlighted in the cornerstone review of its biochemical and translational performance.

The compound’s performance is further detailed in an authoritative workflow guide, which contrasts PF-562271 HCl’s scenario-driven solutions with other kinase inhibitors for reproducibility and selectivity in cell-based cancer assays.

Troubleshooting and Optimization Tips

Common Issues and Solutions

• Poor Solubility: If PF-562271 HCl does not fully dissolve in DMSO, ensure gentle warming and vortexing. Avoid water or ethanol as solvents.
• Compound Precipitation: Rapid dilution into aqueous buffers can cause precipitation. Pre-dilute in DMSO, then add dropwise to pre-warmed media under agitation.
• Loss of Activity: Prolonged storage or repeated freeze-thaw cycles degrade potency. Prepare aliquots and use fresh solutions for each experiment.
• Cell Line Sensitivity: Differential responsiveness may be observed, especially in cells with variable FAK/Pyk2 expression or downstream pathway activation. Use titration studies and confirm target expression by Western blot.
• Data Variability: Ensure consistent cell seeding densities, compound exposure times, and endpoint assays. Include DMSO controls at matched concentrations.

A scenario-driven Q&A resource expands on evidence-based experimental design, optimization, and data interpretation, ensuring rigorous and reproducible results with PF-562271 HCl (SKU A8345).

Future Outlook: PF-562271 HCl in Next-Generation Oncology

As cancer research evolves toward precision medicine, tools like PF-562271 HCl will remain indispensable for elucidating the complex interplay between signaling pathways and tumor microenvironment. The compound’s robust selectivity and reversible inhibition profile support combinatorial approaches, such as co-targeting metabolic enzymes (e.g., EDI3/GPCPD1) or integrating with immune-modulatory therapies.

Emerging evidence, such as from Keller et al. (2023), advocates for multi-dimensional strategies to overcome drug resistance by addressing both kinase signaling and metabolic deregulation in HER2-positive breast cancer. PF-562271 HCl enables such integrated studies, helping researchers unravel resistance mechanisms and identify novel therapeutic targets.

For researchers seeking a validated, high-performance FAK/Pyk2 inhibitor for cancer research, tumor growth inhibition, and advanced pathway analysis, PF-562271 HCl from APExBIO offers a proven, reliable solution backed by extensive protocol support and literature validation.